Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
NEW YORK, April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), is partnering with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month.
- NEW YORK, April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), is partnering with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month.
- ECAN, a leading patient advocacy organization focused on increasing esophageal cancer education, advocacy, awareness, and research, was founded 15 years ago by Mindy Mintz Mordecai following the tragic death of her husband of esophageal cancer.
- Lucid and ECAN are partnering to spread the potentially life-saving message that heartburn (also known as acid reflux or GERD) can lead to highly lethal esophageal cancer and that esophageal cancer is preventable through early precancer detection.
- "This is our 15th Esophageal Cancer Awareness Month, and we are thrilled to see so many companies and individuals paying attention and advocating for early, proactive screening.